Tacrolimus pharmacokinetics in BMT patients

被引:34
作者
Boswell, GW
Bekersky, I
Fay, J
Wingard, J
Antin, J
Weisdorf, D
Maher, R
Fitzsimmons, W
Nash, R
机构
[1] Fujisawa USA Inc, Expt Therapeut, Deerfield, IL 60015 USA
[2] Fujisawa USA Inc, Clin Res & Dev, Deerfield, IL 60015 USA
[3] Fujisawa USA Inc, Drug Dev Project Management, Deerfield, IL 60015 USA
[4] Baylor Univ, Med Ctr, Charles A Sammons Canc Ctr, Dallas, TX USA
[5] Univ S Florida Hlth Sci, Dept Hematol & Oncol, Gainesville, FL USA
[6] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[7] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
[8] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
关键词
bone marrow transplant; tacrolimus (FK506); corticosteroids; methotrexate; pharmacokinetics;
D O I
10.1038/sj.bmt.1701054
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The pharmacokinetics of tacrolimus following its administration as monotherapy or in combination with corticosteroids or methotrexate to 31 BMT patients are presented, All patients received i.v. tacrolimus initially and were subsequently switched to p.o. dosing. Patients received methotrexate by i.v. bolus on post-transplantation days 1, 3, 6 and 11, Patients were started on i.v. corticosteroids beginning on post-transplantation day 7. The noncompartmental pharmacokinetics of tacrolimus based on whole blood concentrations were determined following the i.v. and p.o. doses and were not different at steady-state compared to a single dose, The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 l/kg, Coadministration of methylprednisolone or methotrexate did not significantly alter tacrolimus pharmacokinetics, The p.o. bioavailability was 31-49%. Trough blood concentrations (C-min) at 0 h (pre-dose) and 12 h (post-dose) correlated well to AUC(0-12), indicating that, as in solid organ transplantation, C-min was a good index of drug exposure, Correlation at 0 h (r = 0.92) and at 12 h (r = 0.93) indicate that either time point can be used for therapeutic drug monitoring in patient management.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 21 条
[1]  
BEKERSKY I, 1997, IN PRESS J CLIN PHAR
[2]  
BLOOM EJ, 1994, J CELL BIOCHEM, V18, P90
[3]  
CRAM WR, 1992, APPL PHARMACOKINETIC, P1
[4]   FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation [J].
Fay, JW ;
Wingard, JR ;
Antin, JH ;
Collins, RH ;
Pineiro, LA ;
Blazar, BR ;
Saral, R ;
Bierer, BE ;
Przepiorka, D ;
Fitzsimmons, WE ;
Maher, RM ;
Weisdorf, DJ .
BLOOD, 1996, 87 (08) :3514-3519
[5]  
Gibaldi M., 1982, PHARMACOKINETICS, P409
[6]   PHARMACOKINETICS OF FK506 AFTER INTRAVENOUS AND ORAL-ADMINISTRATION IN PATIENTS AWAITING RENAL-TRANSPLANTATION [J].
GRUBER, SA ;
HEWITT, JM ;
SORENSON, AL ;
BARBER, DL ;
BOWERS, L ;
RYNDERS, G ;
ARRAZOLA, L ;
MATAS, AJ ;
ROSENBERG, ME ;
CANAFAX, DM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (08) :859-864
[7]   PHARMACOKINETICS OF TACROLIMUS IN LIVER-TRANSPLANT PATIENTS [J].
JUSKO, WJ ;
PIEKOSZEWSKI, W ;
KLINTMALM, GB ;
SHAEFER, MS ;
HEBERT, MF ;
PIERGIES, AA ;
LEE, CC ;
SCHECHTER, P ;
MEKKI, QA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :281-290
[8]   CONSENSUS DOCUMENT - THERAPEUTIC MONITORING OF TACROLIMUS (FK-506) [J].
JUSKO, WJ ;
THOMSON, AW ;
FUNG, J ;
MCMASTER, P ;
WONG, SH ;
ZYLBERKATZ, E ;
CHRISTIANS, U ;
WINKLER, M ;
FITZSIMONS, WE ;
LIEBERMAN, R ;
MCBRIDE, J ;
KOBAYASHI, M ;
WARTY, V ;
SOLDIN, SJ .
THERAPEUTIC DRUG MONITORING, 1995, 17 (06) :606-614
[9]  
JUSKO WJ, 1991, TRANSPLANT P, V23, P2732
[10]   Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation [J].
Kershner, RP ;
Fitzsimmons, WE .
TRANSPLANTATION, 1996, 62 (07) :920-926